Search

Displaying results 4151 - 4160 of 4860 in total
  1. Drug

    Leronlimab

    go.drugbank.com/drugs/DB05941
    Investigational

    [L12684] It was first described in the literature in 2001.[A3922] This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.[A192846,A192858,L12684]

  2. Drug

    IMC-1C11

    go.drugbank.com/drugs/DB06101
    Experimental

    It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation.

  3. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding.

  4. Drug

    Virginiamycin S1

    go.drugbank.com/drugs/DB04805
    Experimental

    It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.

  5. Drug

    Chloropyramine

    go.drugbank.com/drugs/DB08800
    Investigational

    It is also indicated for Quincke's edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock.

  6. Drug

    N-methylnicotinamide

    go.drugbank.com/drugs/DB08840
    Investigational

    It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine

  7. Drug

    SynOV1.1

    go.drugbank.com/drugs/DB17539
    Investigational

    It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).

  8. Drug

    AEM-28-14

    go.drugbank.com/drugs/DB17643
    Experimental

    [L45909] It is being investigated for lipid disorders such as homozygous familial hypercholesterolemia.[L45914]

  9. Drug

    ATG002

    go.drugbank.com/drugs/DB05068
    Investigational

    ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors,...

  10. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.